Resource Type

Journal Article 1

Year

2022 1

Keywords

anlotinib 1

chemotherapy 1

short-term relapsed 1

small-cell lung cancer 1

Search scope:

排序： Display mode:

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 766-772 doi: 10.1007/s11684-021-0916-8

Abstract: This study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapyAnlotinib significantly improved median PFS/OS (4.0 vs. 0.7 months, P < 0.0001)/(7.3 vs. 4.4 monthsThe ORR was 4.5%/2.9% in the anlotinib/placebo group (P = 1.000).The DCR in the anlotinib group was higher than that in the placebo group (73.1% vs. 11.8%, P anlotinib treatment was associated

Keywords： anlotinib     chemotherapy     short-term relapsed     small-cell lung cancer    

HTML PDF Collect

Title Author Date Type Operation

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Journal Article